Treatment of depression with maprotiline hydrochloride: multicenter evaluation of efficacy and tolerability.
A multicenter, noncomparative evaluation of the antidepressant effects and tolerability of maprotiline hydrochloride was undertaken. The drug was given to 134 patients between the ages of 17 and 83 years who had either a dysthymic disorder or a major depressive disorder. In most cases, the starting dosage was 75 mg/day with a mean of 71.6 mg/day.
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000873:Anthracenes / Q000627:therapeutic use*; D002319:Cardiovascular System / Q000187:drug effects; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008376:Maprotiline / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged
D000873:Anthracenes; D008376:Maprotiline